Results 13,381-13,400 of 21,090 for speaker:Alan Kelly
- Written Answers — Department of Children and Youth Affairs: Child Detention Centres (20 Nov 2018)
Alan Kelly: 577. To ask the Minister for Children and Youth Affairs if she retains full confidence in the chairperson and members of the board of Oberstown Children Detention Campus in view of the refusal of the chairperson and the board to publish a report (details supplied); and the correspondence she has received from the chairperson which alluded to a threat of resignations if the report was...
- Written Answers — Department of Children and Youth Affairs: Child Detention Centres (20 Nov 2018)
Alan Kelly: 578. To ask the Minister for Children and Youth Affairs the cost of an operational review of Oberstown Children Detention Campus by a company (details supplied). [47874/18]
- Written Answers — Department of Children and Youth Affairs: Child Detention Centres (20 Nov 2018)
Alan Kelly: 579. To ask the Minister for Children and Youth Affairs the cost of the legal advice sought and received by the board of Oberstown Children Detention Campus in relation to the publication of and matters arising from a report (details supplied). [47875/18]
- Written Answers — Department of Children and Youth Affairs: Child Detention Centres (20 Nov 2018)
Alan Kelly: 580. To ask the Minister for Children and Youth Affairs the individual fees and expenses paid to the chairperson and members of the board of Oberstown Children Detention Campus for each of the years 2016, 2017 and to date in 2018. [47877/18]
- Written Answers — Department of Children and Youth Affairs: Child Detention Centres (20 Nov 2018)
Alan Kelly: 581. To ask the Minister for Children and Youth Affairs if she has received the 2016 and 2017 annual accounts for Oberstown Children Detention Campus in accordance with section 173 of the Children's Act 2001; and if so, her plans to publish same. [47878/18]
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: The witnesses are very welcome and I thank them for their contributions. The committee has written its report and several of us have argued and fought for various different organisations. I and Deputy Brassil and others have worked closely with the Alpha-1 foundation in its fight. In the last week or so, we secured a guarantee on the 19 remaining patients that were on clinical trials. I...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: Who decides?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: My point is this is beyond a stakeholder.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: This is an area to which we might return. The issue of genetics is very interesting.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: Have we a copy of this? None of us has a copy of this.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I do not want to hold up the meeting but I just wanted to ensure I was not the only person who has not seen it.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: It is obvious that we need an extensive national medicines policy to be driven at departmental level. It is to be hoped that will happen in the next Government. Mr. Judge stated that the Minister cannot get involved in drug reimbursement decisions. If that is so, what happened in the case of Orkambi? Did the Minister become involved contrary to the Act referred to by Mr. Judge or did he...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: That is what happened with Orkambi.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: That is so in one case I am aware of.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: About what percentage?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: To save time, because this is very statistics-orientated, I might supply a list and the witnesses might come back to me. Would that be okay?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: That is what I am asking about.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I know that.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: That needs to be looked at.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I am not leaving here until we get an answer to my last question. What Mr. Hennessy has just said is of no comfort. This is going to explode in everyone's face. The witnesses all know what I am talking about. One cannot discriminate between two people on the basis that one got cancer at one point and another got cancer a year later. There was a crisis in this country and the Government...